Literature DB >> 19192111

Molecular mechanism of the interaction between activated factor XIII and its glutamine donor peptide substrate.

K Pénzes1, K E Kövér, F Fazakas, G Haramura, L Muszbek.   

Abstract

BACKGROUND: Activated factor XIII (FXIII), a dimer of truncated A-subunits (FXIII-A2*), is a transglutaminase that crosslinks primary amines to peptide-bound glutamine residues. Because in the few natural substrates of FXIII-A2* no consensus sequence could be identified around the reactive glutamine, studying the interaction between individual substrates and FXIII-A2* is of primary importance. Most of the alpha2-plasmin inhibitor (alpha2PI) molecules become truncated by a plasma protease, and the truncated isoform (N1-alpha2PI) is an important substrate of FXIII-A2*. The crosslinking of N1-alpha2PI to fibrin plays a major role in protecting fibrin from fibrinolysis.
METHODS: We studied the interaction of FXIII-A2* with its dodecapeptide glutamine donor substrate, N1-alpha2PI(1-12), the sequence of which corresponds to the N-terminal sequence of N1-alpha2PI. Kinetic parameters for N1-alpha2PI(1-12) and for its truncated or synthetic mutants were determined by a spectrophotometric assay. The interaction of N1-alpha2PI(1-12) with FXIII-A2* was investigated by proton nuclear magnetic resonance (NMR) and saturating transfer difference (STD) NMR. RESULTS AND
CONCLUSIONS: Kinetic experiments with peptides in which the Asn1 residue was either truncated or replaced by alanine and proton NMR analysis of the FXIII-A2*-N1-alpha2PI(1-12) complex demonstrated that Asn1 is essential for effective enzyme-substrate interaction. Experiments with C-terminally truncated peptides proved that amino acids 7-12 are essential for the interaction of N1-alpha2PI(1-12) with the enzyme, and suggested the existence of a secondary binding site on FXIII-A2*. Hydrophobic residues, particularly Leu10 and the C-terminal Lys12, seemed to be especially important in this respect, and direct interaction between hydrophobic C-terminal residues and FXIII-A2* was demonstrated by STD NMR.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19192111     DOI: 10.1111/j.1538-7836.2009.03291.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  6 in total

1.  Evaluating factor XIII specificity for glutamine-containing substrates using a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay.

Authors:  Prakash G Doiphode; Marina V Malovichko; Kelly Njine Mouapi; Muriel C Maurer
Journal:  Anal Biochem       Date:  2014-04-19       Impact factor: 3.365

2.  Discovery of potent and specific dihydroisoxazole inhibitors of human transglutaminase 2.

Authors:  Cornelius Klöck; Zachary Herrera; Megan Albertelli; Chaitan Khosla
Journal:  J Med Chem       Date:  2014-10-31       Impact factor: 7.446

3.  Ranking reactive glutamines in the fibrinogen αC region that are targeted by blood coagulant factor XIII.

Authors:  Kelly Njine Mouapi; Jacob D Bell; Kerrie A Smith; Robert A S Ariëns; Helen Philippou; Muriel C Maurer
Journal:  Blood       Date:  2016-03-07       Impact factor: 22.113

4.  A non-reactive glutamine residue of alpha2-antiplasmin promotes interactions with the factor XIII active site region.

Authors:  D B Cleary; P G Doiphode; T M Sabo; M C Maurer
Journal:  J Thromb Haemost       Date:  2009-08-19       Impact factor: 5.824

5.  Allosteric Inhibition of Factor XIIIa. Non-Saccharide Glycosaminoglycan Mimetics, but Not Glycosaminoglycans, Exhibit Promising Inhibition Profile.

Authors:  Rami A Al-Horani; Rajesh Karuturi; Michael Lee; Daniel K Afosah; Umesh R Desai
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

6.  Functionalizing Fibrin Hydrogels with Thermally Responsive Oligonucleotide Tethers for On-Demand Delivery.

Authors:  Chase S Linsley; Kevin Sung; Cameron White; Cara A Abecunas; Bill J Tawil; Benjamin M Wu
Journal:  Bioengineering (Basel)       Date:  2022-01-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.